Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency

Check for updates

Stefania Drovandi[1,2,3,44], Beata S. Lipska-Ziętkiewicz[4,5,44], Fatih Ozaltin[6], Francesco Emma[7], Bora Gulhan[6], Olivia Boyer[8,9], Agnes Trautmann[1], Hong Xu[10], Qian Shen[10], Jia Rao[10], Korbinian M. Riedhammer[11,12], Uwe Heemann[12], Julia Hoefele[11], Sarah L. Stenton[11,13], Alexey N. Tsygin[14], Kar-Hui Ng[15], Svitlana Fomina[16], Elisa Benetti[17], Manon Aurelle[18], Larisa Prikhodina[19], Michiel F. Schreuder[20], Mansoureh Tabatabaeifar[1], Maciej Jankowski[5], Sergey Baiko[21], Jianhua Mao[22], Chunyue Feng[22], Cuihua Liu[23], Shuzhen Sun[24], Fang Deng[25], Xiaowen Wang[26], Stéphanie Clavé[27], Małgorzata Stańczyk[28], Irena Bałasz-Chmielewska[29], Marc Fila[30], Anne M. Durkan[31], Tanja Kersnik Levart[32], Ismail Dursun[33], Nasrin Esfandiar[34], Dorothea Haas[35], Anna Bjerre[36,37], Ali Anarat[38], Marcus R. Benz[39], Saeed Talebi[40], Nakysa Hooman[41], Gema Ariceta[42], PodoNet Consortium[43], mitoNET Consortium[43], CCGKDD Consortium[43] and Franz Schaefer[1]

[1]Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany; [2]Division of Nephrology, Dialysis, Transplantation, Giannina Gaslini Children's Hospital, Genoa, Italy; [3]Division of Nephrology, Dialysis and Transplantation, Department of Internal Medicine, Ospedale Policlinico San Martino and University of Genoa, Genoa, Italy; [4]Rare Diseases Centre, Medical University of Gdańsk, Gdańsk, Poland; [5]Department of Biology and Medical Genetics, Clinical Genetics Unit, Medical University of Gdańsk, Gdańsk, Poland; [6]Division of Pediatric Nephrology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey; [7]Department of Pediatric Subspecialties, Division of Nephrology and Dialysis, Bambino Gesù Childrens Hospital, IRCCS, Rome, Italy; [8]Assistance Publique–Hôpitaux de Paris (APHP), Necker-Enfants Malades Hospital, Pediatric Nephrology, MARHEA and SNI reference centers, Paris, France; [9]Imagine Institute, Paris University, Paris, France; [10]Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China; [11]Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; [12]Department of Nephrology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany; [13]Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; [14]Department of Pediatric Nephrology, National Medical and Research Centre for Children's Health, Moscow, Russia; [15]Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; [16]Department of Pediatric Nephrology, Institute of Nephrology of NAMS of Ukraine, Kiev (Kyiv), Ukraine; [17]Pediatric Nephrology, Dialysis and Transplant Unit, Department of Women's and Children's Health, Padua University Hospital, Padua, Italy; [18]Department of Pediatric Nephrology, University Children's Hospital, Lyon, France; [19]Research and Clinical Institute for Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia; [20]Department of Pediatric Nephrology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Amalia Children's Hospital, Nijmegen, the Netherlands; [21]Department of Pediatrics, Belarusian State Medical University, Minsk, Belarus; [22]Department of Nephrology, The Children Hospital of Zhejiang, University School of Medicine, Hangzhou, China; [23]Department of Nephrology and Rheumatology, Henan Children's Hospital, Zhengzhou, China; [24]Department of Pediatric Nephrology and Rheumatism and Immunology, Shandong Provincial Hospital, Jinan, China; [25]Department of Nephrology, Anhui Provincial Children's Hospital, Hefei, China; [26]Department of Nephrology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China; [27]Department of Multidisciplinary Pediatrics, University Hospital of Marseille, Marseille, France; [28]Department of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital Research Insitute, Lodz, Poland; [29]Department of Pediatrics, Nephrology and Hypertension, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland; [30]Pediatric Nephrology Department, CHU Arnaud de Villeneuve, Montpellier University Hospital, Montpellier, France; [31]Department of Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; [32]Department of Nephrology, Division of Paediatrics, University Medical Centre, Bohoričeva, Ljubljana, Slovenia; [33]Department of Pediatrics, Division of Nephrology, Erciyes University, Faculty of Medicine, Kayseri, Turkey; [34]Pediatric Nephrology Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran; [35]Division of Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany; [36]Division of Pediatric and Adolescent Medecine, Oslo University Hospital, Oslo, Norway; [37]Institute of Clinical Medicine, University of Oslo, Oslo, Norway; [38]Department of Pediatric Nephrology, Çukurova University, Adana, Turkey; [39]Pediatric Nephrology, Pediatric Medicine Dachau, Dachau, Germany; [40]Department of

Correspondence: *Stefania Drovandi, Division of Nephrology, Dialysis, Transplantation, Giannina Gaslini Children's Hospital, Genoa, Italy. E-mail:* stefania.drovandi@gmail.com

[43]Members of the PodoNet Consortium, mitoNET Consortium, and CCGKDD Consortium are listed in the Appendix.

[44]SD and BSL-Z contributed equally.

Medical Genetics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; [41]Department of Pediatrics, Aliasghar Clinical Research Development Center, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran; and [42]Department of Pediatric Nephrology, University Hospital Vall d'Hebron, Barcelona, Spain

Primary Coenzyme Q10 (CoQ$_{10}$) deficiency is an ultra-rare disorder caused by defects in genes involved in CoQ$_{10}$ biosynthesis leading to multidrug-resistant nephrotic syndrome as the hallmark kidney manifestation. Promising early results have been reported anecdotally with oral CoQ$_{10}$ supplementation. However, the long-term efficacy and optimal prescription remain to be established. In a global effort, we collected and analyzed information from 116 patients who received CoQ$_{10}$ supplements for primary CoQ$_{10}$ deficiency due to biallelic pathogenic variants in either the _COQ2_, _COQ6_ or _COQ8B_ genes. Median duration of follow up on treatment was two years. The effect of treatment on proteinuria was assessed, and kidney survival was analyzed in 41 patients younger than 18 years with chronic kidney disease stage 1-4 at the start of treatment compared with that of an untreated cohort matched by genotype, age, kidney function, and proteinuria. CoQ$_{10}$ supplementation was associated with a substantial and significant sustained reduction of proteinuria by 88% at 12 months. Complete remission of proteinuria was more frequently observed in _COQ6_ disease. CoQ$_{10}$ supplementation led to significantly better preservation of kidney function (5-year kidney failure-free survival 62% vs. 19%) with an improvement in general condition and neurological manifestations. Side effects of treatment were uncommon and mild. Thus, our findings indicate that all patients diagnosed with primary CoQ$_{10}$ deficiency should receive early and life-long CoQ$_{10}$ supplementation to decelerate the progression of kidney disease and prevent further damage to other organs.

Hereditary podocytopathies account for up to 30% of steroid-resistant nephrotic syndrome (SRNS) cases in children.[1] This etiologically heterogeneous group of monogenic disorders is characterized by a poor long-term prognosis, with inevitable progression to end-stage kidney disease (ESKD) and a lack of effective therapies.[2] Proteinuria in these disorders is resistant to immunosuppressive therapy, leaving nonspecific pharmacologic proteinuria lowering with renin-angiotensin-aldosterone system (RAAS) inhibition as the only therapeutic option. One notable exception may be a group of mitochondrial disorders that cause SRNS from primary coenzyme Q10 (CoQ$_{10}$) deficiency. These disorders are responsible for up to 5% of genetic SRNS cases[3–5] and are caused by recessive pathogenic variants in genes involved in CoQ$_{10}$ biosynthesis, mainly _COQ2_, _COQ6_, and _COQ8B_.[6,7] CoQ$_{10}$ deficiency causes bioenergetic impairment, oxidative damage, and apoptosis of affected cells.[8] Podocytes are especially vulnerable because of their high energy requirement, and podocyte mitochondrial dysfunction causes a disruption of the glomerular filtration barrier.[9]

Experimental work has demonstrated that CoQ$_{10}$ supplementation can rescue podocyte survival and prevent kidney failure in CoQ$_{10}$ deficiency by reducing oxidative stress and preventing H$_2$S oxidation.[8] Several case reports and small retrospective studies have suggested that oral CoQ$_{10}$ administration can reduce proteinuria in affected patients[10–14] and might also improve some of the extrarenal manifestations of CoQ$_{10}$ deficiency.[15,16]

To overcome the limitations of small case studies in this ultrarare condition, we recently gathered clinical information from a cohort of >250 patients with primary CoQ$_{10}$ deficiency collected from 3 international registries, medical society member surveys, and the published literature.[17] Published original cases were updated whenever possible. The available extended longitudinal information from 116 patients treated with CoQ$_{10}$ supplements allowed us to evaluate the efficacy and safety of this therapy and to compare short- and long-term outcomes with patients who did not receive CoQ$_{10}$ treatment.

METHODS

Study population and design

As a joint initiative of the European Rare Kidney Disease Network (ERKNet), the European Society for Pediatric Nephrology (ESPN), and the PodoNet Consortium, in collaboration with the Chinese Children Genetic Kidney Disease Database (CCGKDD), the German Network for Mitochondrial Disorders (mitoNET), the European Study Consortium for Chronic Kidney Disorders Affecting Pediatric Patients (ESCAPE) Clinical Research Network, and the Asian Society for Pediatric Nephrology, we assembled a global cohort of 251 patients affected by _primary CoQ$_{10}$ deficiency_ due to biallelic (likely) pathogenic variants in _COQ2_, _COQ6_, or _COQ8B_ (see the study by Drovandi et al.[17] for further details of data collection). In this study, we analyzed a subset of 116 individuals who received CoQ$_{10}$ supplementation for treatment efficacy and safety. Changes in proteinuria and estimated glomerular filtration rate (eGFR), the general clinical condition, and neurologic signs and symptoms on treatment were assessed. Changes in proteinuria and eGFR from the pretreatment baseline were recorded at 3 and 6 months and subsequently every 6 months. The general clinical condition and neurologic signs

and symptoms at any time point during treatment were compared with the status before treatment start.

Fifteen patients with missing baseline data for proteinuria or eGFR, 48 patients with ESKD at start of treatment (17 transplanted), 2 patients with temporarily interrupted therapy, and 4 patients with baseline proteinuria in the normal range were excluded from the analysis of change in proteinuria and annual eGFR loss. To explore a potential longer-term treatment impact on global kidney function, kidney survival rates of patients aged <18 years with chronic kidney disease (CKD) stage 1–4 at start of treatment and a minimum follow-up time of 1 month ($n = 41$) were compared with those of a matched control group of 41 untreated subjects from the CoQ$_{10}$ deficiency cohort. The treated and untreated patients were individually matched by genotype (*COQ2/COQ6/COQ8B*), age (±3 years in children aged <10 years, older children pooled), kidney function (same CKD stage or eGFR difference ≤10 ml/min per 1.73 m^2), and proteinuria (absent/subnephrotic range/nephrotic range proteinuria). The date of ESKD attainment or the last observation with a functioning kidney was used for kidney survival analysis. Three patients with history of acute kidney injury during the treatment course were excluded from the analysis. All patient-related data were collected in a completely deidentified manner; thus, all analyses were performed on fully anonymized data sets.

Proteinuria analysis

Locally used methods for quantitation of proteinuria included urinary albumin concentration, protein-to-creatinine ratio, and albumin-to-creatinine ratio from spot urine samples, as well as urinary protein excretion or urinary albumin excretion from 24-hour urine collections.

The same method of proteinuria measurement was used on all observations of a subject to assess intraindividual changes.

The proteinuria response to CoQ$_{10}$ treatment was assessed as (i) percentage change from pretreatment baseline, (ii) absolute reduction of proteinuria to ≤1.5 mg/mg, and (iii) attainment of complete remission, defined as ≤0.2 mg/mg (20 mg/mmol) urine protein-to-creatinine ratio.

For the logistic regression analysis, 50% proteinuria reduction relative to baseline was used as partition value. In 15 patients in whom proteinuria was missing, responsiveness to treatment was assumed in case of normalization of serum albumin (>35 g/L).

Potential associations between genotype and responsiveness to CoQ$_{10}$ treatment were analyzed with respect to proteinuria reduction in patients with CKD stage 1 to 4 at start of treatment and uninterrupted therapy during the observation period. Individuals carrying biallelic truncating variants were compared with patients carrying at least 1 missense variant or missense variants only.

Kidney function analysis

Glomerular filtration rate was estimated using the Schwartz bedside formula in pediatric patients and the Modification of Diet in Renal Disease formula[11] or CKD Epidemiology Collaboration equation in adult patients.

In cases where eGFR was reported only by Kidney Disease: Improving Global Outcomes (KDIGO) CKD stage, the median eGFR per stage was used to approximate individual eGFR. The average annual eGFR decline was estimated by the difference between baseline eGFR and the latest available eGFR divided by time interval in years. Attainment of ESKD was defined by the first eGFR measurement <15 ml/min per 1.73 m^2 or initiation of kidney replacement therapy (dialysis or preemptive transplantation).

Analysis of neurologic status and general clinical condition

Data on extrarenal manifestations, especially neurologic disease, and general clinical condition were collected. Neurologic disease modification during CoQ$_{10}$ treatment was defined on the basis of the available clinical descriptions provided by the reporting centers. In the *COQ6* group, hearing impairment was specifically investigated. The general clinical status was analyzed on the basis of physical performance, feeding ability, growth and weight gain, and the frequency of hospitalization.

Statistical analysis

For descriptive analyses, data were presented as median and interquartile range (IQR). Categorical variables were presented as percentage. Continuous variables were compared using Wilcoxon test. $P < 0.05$ was considered statistically significant.

Kidney survival rates were calculated using Kaplan-Meier lifetable analysis, and survival rates of treated and untreated cohorts were compared using log-rank test.

Logistic regression modeling was employed to examine associations between multiple factors and proteinuria responsiveness. Associations of factors with kidney survival were assessed using univariate Cox regression analyses. Possible associations between genotypes and phenotypes were assessed using 2 × 2 contingency tables and Fisher exact tests. Statistical analyses were performed using GraphPad Prism v9.3.1 (GraphPad Software, Inc.).

RESULTS

The patient characteristics at baseline are listed in Table 1. CoQ$_{10}$ supplementation was initiated in 116 individuals. Either ubiquinone (ubidecarenone) *or* ubiquinol was prescribed (information on formulation was available in 72 of 116 cases). Supplementation was administered to the patients at variable empirical doses between 3 and 60 mg/kg per day in 2 to 3 divided doses (dosage information available in 97 of 116 cases). In 66% of the patients, treatment was started with full target dose, whereas the dose was gradually up titrated in the remaining cases (Table 2). The median follow-up time on CoQ$_{10}$ supplementation was 1.3 (IQR, 0.6–2.8) years, 1.1 (IQR, 0.2–3.3) years, and 2.0 (IQR, 1–3.6) years in the *COQ2*, *COQ6*, and *COQ8B* groups, respectively.

CoQ$_{10}$ determination in cells and tissues

Total CoQ$_{10}$ content was determined in white blood cells (leukocytes), skin fibroblasts, or skeletal muscle biopsies in 21 patients. Baseline CoQ$_{10}$ levels in fibroblasts and muscle tissue were reduced in all 15 subjects assessed. Conversely, baseline CoQ$_{10}$ levels in leukocytes were reduced in 1 of 4 subjects assessed. Three patients underwent repeated measurements of leukocyte CoQ$_{10}$ concentrations during CoQ$_{10}$ supplementation. In these subjects, mean CoQ$_{10}$ levels increased by 208%, 223%, and 238%, respectively, during treatment.

Proteinuria response to CoQ$_{10}$ supplementation

Proteinuria rapidly diminished after initiation of CoQ$_{10}$ treatment, by a median of 88% (IQR, 20%–98%) at the end of the first treatment year ($P < 0.0001$) and remained at

Table 1 | Characteristics of the overall cohort of 251 patients with primary CoQ$_{10}$ deficiency treated (n = 116) or not treated (n = 135) with oral CoQ$_{10}$ supplementation, and of the subcohort receiving oral CoQ$_{10}$ at age <18 years and with CKD stage 1 to 4 at start of treatment (n = 41) and matched untreated controls (n = 41)

	Overall cohort (n = 251)						Matched cohort (n = 82)					
	COQ2 (n = 63)		COQ6 (n = 48)		COQ8B (n = 140)		COQ2 (n = 30)		COQ6 (n = 16)		COQ8B (n = 36)	
Characteristic	Treated	Not treated	Treated	Not treated	Treated	Not treated	Treated	Not treated	Treated	Not treated	Treated	Not treated
Total no. of patients	32	31	24	24	60	80	15	15	8	8	18	18
No. of female patients	13	17	8	8	29	36	5	6	6	3	8	8
Age at first disease manifestation, yr	1.5 (0.8–2.5)	0.8 (0.1–1.6)	1.1 (0.6–3)	2.3 (1–4.5)	5.2 (2.7–7)	11.9 (7–16.2)	0.8 (0.2–2)	0.9 (0.5–1.7)	0.8 (0.1–1.8)	1.7 (1.2–2.8)	3 (1.4–4.5)	5.5 (2.3–13.3)
Age at first kidney disease manifestation, yr	1.6 (0.8–2.5)	0.9 (0.3–1.9)	1.3 (0.6–3.8)	2.4 (1.2–4.5)	9 (4.6–11.8)	11.8 (7–16)	0.8 (0.3–2)	1 (0.6–1.8)	1.1 (0.5–1.7)	2.1 (1.7–2.9)	4.5 (2–9)	6.6 (4.1–13.2)
FSGS on kidney biopsy	77 (17/22)	57 (8/14)	50 (7/14)	82 (18/22)	62 (18/29)	82 (45/55)	53 (8/15)	53 (8/15)	50 (4/8)	75 (6/8)	33 (6/18)	83 (15/18)
Follow-up time, yr	2.4 (1.1–6.4)	0.5 (0.1–2.8)	3.4 (1–11)	5 (2.3–5.4)	5 (2.5–7.8)	2.8 (0.8–5.8)	1.5 (0.8–2.8)	8.7 (1.1–17.6)	5.2 (1.8–9.2)	3 (2.2–8.9)	5.1 (2.8–7.1)	5.7 (3.8–9.2)
ESKD at disease onset	3 (1/32)	26 (8/31)	17 (4/24)	4 (1/24)	20 (12/60)	25 (20/80)	N/A	N/A	N/A	N/A	N/A	N/A
Time from first manifestation to ESKD, yr	1 (0.95–4.1)	0.05 (0–0.75)	1 (0.8–2.1)	0.9 (0.3–2)	1.35 (0.4–4.3)	1 (0–3.8)	2.5 (1.7–4.1)	1 (0.3–1.6)	N/A	1.2 (0.7–1.9)	1.5 (0.9–4.6)	4 (2.8–6.1)
Extrarenal manifestations	78 (25/32)	67 (21/31)	92 (22/24)	79 (19/24)	30 (18/60)	26 (21/80)	73 (11/15)	80 (12/15)	100 (8/8)	75 (6/8)	22 (4/18)	33 (6/18)
Deceased	19 (6/32)	32 (10/31)	0 (0/24)	21 (5/24)	0 (0/60)	7 (6/80)	33 (5/15)	20 (3/15)	0 (0/8)	0 (0/8)	0 (0/18)	0 (0/18)
Age at death, yr	1.1 (0.6–2.2)	0.45 (0.0–0.5)	N/A	6.5 (5.7–12)	N/A	13.9 (12.6–19.5)	1.2 (1–2.6)	0.5 (0.4–0.5)	N/A	N/A	N/A	N/A

CKD, chronic kidney disease; CoQ$_{10}$, coenzyme Q10; ESKD, end-stage kidney disease; FSGS, focal segmental glomerular sclerosis; N/A, not applicable.
Numbers represent percentage (number of affected patients/informative number of patients) and median (interquartile range), as appropriate. The patients were individually matched with untreated patients from the CoQ$_{10}$ deficiency cohort by genotype (COQ2/COQ6/COQ8B), age (±3 years in children aged <10 years, older children pooled), kidney function (same CKD stage or estimated glomerular filtration rate difference ≤10 ml/min per 1.73 m²), and proteinuria (absent/subnephrotic range/nephrotic range proteinuria).

≈40% of the baseline level during up to 5 years of follow-up (Figure 1).

Proteinuria was maximally reduced by >50% relative to baseline in 56% of *COQ2*, 42% of *COQ6*, and 44% of *COQ8B* patients (Table 2). When excluding individuals with ESKD at baseline, the percentage of responders increased to 67% for patients with *COQ2* and *COQ6* and 60% for subjects with *COQ8B* disease.

Complete remission of proteinuria was achieved in 23% of the patients with preserved kidney function (CKD 1–4) at start of treatment, corresponding to 40% of the responders, according to the 50% proteinuria reduction criterion. Complete remission was observed in 58% of *COQ6*, 16% of *COQ8B*, and 6% of *COQ2* patients.

Proteinuria responsiveness was independent of age, eGFR, proteinuria level, time since first disease manifestation, histopathologic features, and CoQ$_{10}$ dosage (Table 3). Proteinuria responsiveness (≥50% reduction in proteinuria from pretreatment baseline) also did not differ between the genetic disease subgroups; however, *COQ6* cohort showed significantly higher rate of complete remission of proteinuria (P = 0.035).

Treatment responsiveness was also assessed according to the type of genetic abnormality present.

All treated patients with *COQ2* and *COQ6* disease carried at least 1 missense variant except for 1 *COQ2* individual. In the *COQ8B* cohort, 30% of patients carried biallelic truncating variants.

The responder rates to CoQ$_{10}$ treatment did not differ significantly between patients carrying biallelic truncating variants (25% of patients achieved complete remission), patients carrying biallelic missense variants (34%), and those who were compound heterozygous for missense and truncating variants (35%).

Kidney survival

The kidney survival of 41 children with CKD stage 1 to 4 receiving CoQ$_{10}$ supplementation was compared with that of a matched untreated control cohort (Figure 2). Altogether, 9 patients in the treated and 28 patients in the untreated group progressed to ESKD. The median (IQR) annualized rate of eGFR loss was 0 (0–20) ml/min per 1.73 m² per year in the CoQ$_{10}$-treated patients versus 18 (7–49) ml/min per 1.73 m² in the untreated controls (P = 0.0148). The 5-year kidney survival rate was 62% compared with 19% in the untreated group (P < 0.005; Figure 2).

In the *COQ2* subcohort, the median (IQR) annual eGFR loss was 6.6 (0–27) ml/min per 1.73 m² in the 32 CoQ$_{10}$-treated patients and 46.2 (23–185) ml/min per 1.73 m² in the untreated group. Survival analysis showed a nominal improvement of kidney survival with CoQ$_{10}$ supplementation (2-year survival, 78% vs. 33%) without statistical significance (P = 0.282). One patient showed

Table 2 | Characteristics of the treated cohort, treatment strategies, and response to oral CoQ$_{10}$ supplementation

	CoQ$_{10}$-treated cohort ($n = 116$)		
Characteristic	*COQ2* ($n = 32$)	*COQ6* ($n = 24$)	*COQ8B* ($n = 60$)
Age at start of CoQ$_{10}$ supplementation, yr	2.6 (1–12.9)	5 (1.8–8.15)	11 (8.1–17.2)
Time from disease onset to CoQ$_{10}$ start, yr	0.8 (0.2–1.75)	3 (0.9–6.6)	1.8 (0.4–5)
eGFR at start of CoQ$_{10}$ supplementation (ml/min per 1.73 m^2)[a]	100 (96–100)	100 (100–100)	91 (75–117)
CKD stage			
1	41 (13/32)	58 (14/24)	30 (18/60)
2	0 (0/32)	0 (0/24)	10 (6/60)
3	3 (1/32)	0 (0/24)	8 (2/60)
4	6 (2/32)	0 (0/24)	0 (0/60)
5/KRT	34 (11/32)	37 (9/24)	47 (28/60)
Unknown eGFR	16 (5/32)	4 (1/24)	10 (6/60)
RAASi at start of CoQ$_{10}$ supplementation	25 (8/32)	33 (8/24)	40 (24/60)
RAASi withdrawal during CoQ$_{10}$ supplementation	0 (0/8)	37 (3/8)	4 (1/24)
IS therapy at start of CoQ$_{10}$ supplementation	37 (12/32)	29 (7/24)	17 (10/60)
IS withdrawal during CoQ$_{10}$ supplementation	50 (6/12)	43 (3/7)	20 (2/10)
Formulation (ubiquinone/ubiquinol/unknown)	16/6/10	14/0/10	35/1/24
CoQ$_{10}$ dose, mg/kg per day	30 (30–30)	29 (20–30)	20 (15–30)
Observation time on CoQ$_{10}$ supplementation, yr	1.3 (0.6–2.8)	1.1 (0.2–3.3)	2.0 (1.0–3.6)
>50% Proteinuria reduction[a]	66 (14/21)	66 (10/15)	59 (19/32)
Proteinuria reduction to UPCR <1.5 mg/mg[a]	44 (7/16)	58 (7/12)	32 (8/25)
Complete remission (UPCR ≤0.2 mg/mg)[a]	6 (1/16)	58 (7/12)	16 (4/25)
Progression to ESKD during CoQ$_{10}$ supplementation	16 (5/32)	0 (0/24)	12 (7/60)
Improvement of general clinical condition[b]	19 (6/32)	21 (5/24)	7 (4/60)
Improvement of neurologic symptoms	9 (3/32)	4 (1/24)	3 (2/60)
Adverse effects attributed to CoQ$_{10}$ supplementation	6 (2/32)	4 (1/24)	3 (2/60)

CKD, chronic kidney disease; CoQ$_{10}$, coenzyme Q10; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; IS, immunosuppressive treatment; KRT, kidney replacement treatment; RAASi, renin-angiotensin-aldosterone system inhibitors; UPCR, urine protein-to-creatinine ratio.
[a]Patients with CKD stage 1 to 4 at start of treatment (i.e., patients already in ESKD excluded) and uninterrupted therapy.
[b]Physical performance/feeding ability/weight gain/growth/hospitalization frequency.
Numbers represent percentage (number of affected patients/informative number of patients) and median (interquartile range), as appropriate.

late disease progression to ESKD after 14 years of follow-up on treatment.

Only 8 patients with *COQ6* disease and preserved eGFR received CoQ$_{10}$ supplementation. All these patients retained their kidney function during observational period (median annualized loss, 0 ml/min per 1.73 m^2), 3 of them reached 5 years of follow-up with kidney survival of 100%, whereas all matched untreated control patients progressed to ESKD within 2.3 years ($P = 0.0049$). Two patients with extended follow-up showed preserved kidney function after 9 and 10 years of treatment, respectively.

Among the 32 pre-ESKD *COQ8B* patients started on CoQ$_{10}$ supplementation at a median eGFR of 91.5 (75–117) ml/min per 1.73 m^2, the median annualized eGFR decline rate was 7.2 (0–26.7) ml/min per 1.73 m^2, compared with 17.7 ml/min per 1.73 m^2 in untreated patients. ESKD-free survival 5 years after start of treatment was 55%, compared with 29.5% in the matched untreated *COQ8B* patient group ($P = 0.5779$). One patient showed late progression to ESKD after 10 years on treatment.

CoQ$_{10}$ dosage ($P = 0.021$) and younger age ($P = 0.003$) at treatment initiation were identified by univariate Cox regression analysis as ESKD risk factors while on CoQ$_{10}$ treatment, whereas eGFR, proteinuria level, time since first disease manifestation, and histopathologic features were not associated with ESKD outcome (Table 3).

Nonrenal effects of CoQ$_{10}$ supplementation

Neurometabolic manifestations are a hallmark of *COQ2* disease. Six of the 32 CoQ$_{10}$-supplemented patients, compared with 10 of 31 matched untreated patients, had a fatal outcome following progressive neurologic deterioration. The deaths occurred after a median 0.9 (0.3–2.2) years of treatment. Five treated patients developed refractory seizures that progressed to severe encephalopathy despite treatment, 2 in the context of multiorgan failure. On the other hand, an improved neuromuscular status was reported in 3 patients, characterized by muscular tone/strength and ameliorated motor development. In another 2 children, neurologic symptoms (epilepsy and headache with phonophobia and photophobia) subsided with CoQ$_{10}$ supplementation.

Progressive sensorineural deafness is a specific manifestation in *COQ6* disease. Of 11 CoQ$_{10}$-supplemented *COQ6* children who underwent audiometric examinations, 1 case showed improved hearing function within 15 months of therapy, 1 case showed further deterioration of hearing impairment over time, and, in 2 cases, hearing impairment was first diagnosed after 8 and 16 months of CoQ$_{10}$ supplementation, respectively. In 1 child with *COQ6* disease, an improvement of psychomotor delay on treatment was described. Among the 60 CoQ$_{10}$-supplemented *COQ8B* patients, 9 had neurologic disease manifestations diagnosed before treatment. In 2 of these patients, epileptic seizures subsided with CoQ$_{10}$ supplementation during a median

Figure 1 | Change in proteinuria (expressed as percent of baseline value) during coenzyme Q10 (CoQ$_{10}$) supplementation over 5 years of follow-up. Patients with missing proteinuria data at baseline, temporarily interrupted therapy, baseline proteinuria in normal range, or end-stage kidney disease at baseline were excluded from analysis.

follow-up time of 13 months, and in another 2 cases, a "general improvement" of the neurologic condition was reported.

An improved general clinical condition on CoQ$_{10}$ supplementation was noticed in 6 of 32 *COQ2*, 5 of 24 *COQ6*, and 4 of 60 *COQ8B* patients (i.e., 12% of all patients).

CoQ$_{10}$ adverse effects

Apparent adverse effects of therapy were reported in 5 children (4%), in all cases related to the gastrointestinal tract.

Symptoms ranged from loss of appetite, nausea, and vomiting to abnormal stool frequency/form. In 2 cases, the adverse effects led to discontinuation of CoQ$_{10}$ after a few months on treatment.

A 27-year-old woman reported a spontaneous abortion during CoQ$_{10}$ supplementation; she interrupted the treatment when she learned of her second pregnancy until the end of lactation. Notably, proteinuria increased during treatment discontinuation.

Concomitant medications

At the time of CoQ$_{10}$ initiation, 40 patients (34%) were receiving RAAS inhibitors (29 angiotensin-converting enzyme inhibitors, 2 angiotensin receptor blockers, 8 combined therapy, and 1 unknown). Three patients discontinued RAAS inhibitors, and 1 patient went from combined therapy to angiotensin-converting enzyme inhibitor monotherapy after remission of proteinuria.

At the time of diagnosis, 12 of the 99 nontransplanted patients were receiving calcineurin inhibitors and/or steroids as first- or second-line treatment for steroid-resistant nephrotic syndrome. In 10 of the 12 patients, immunosuppression was discontinued between 2 months and 3 years after CoQ$_{10}$ initiation; only 2 patients were receiving cyclosporin at last observation.

Neither concomitant angiotensin-converting enzyme inhibitor treatment (Table 3) nor immunosuppressive treatment (data not shown) was correlated with proteinuria

Table 3 | Univariate logistic regression analysis of proteinuria reduction and univariate Cox proportional hazard regression analyses of progression to ESKD during CoQ$_{10}$ supplementation

Variable	>50% Proteinuria reduction[a] OR (95% CI)	P value	Proteinuria reduction to UPCR ≤1.5 mg/mg OR (95% CI)	P value	Complete remission (UPCR ≤0.2 mg/mg) OR (95% CI)	P value	Progression to ESKD HR (95% CI)	P value
Genetic disease entity (reference: *COQ8B* deficiency)								
COQ2 deficiency	0.54 (0.07–2.93)	0.501	0.56 (0.06–3.91)	0.564	0.22 (0–2.91)	0.268	2.4 (0.69–8.10)	0.148
COQ6 deficiency	0.76 (0.09–4.26)	0.763	2.80 (0.20–70)	0.448	17.5 (1.6–471)	**0.035**	0.03 (0–4799)	0.576
Age at CoQ$_{10}$ treatment initiation, yr	1.36 (0.29–7.38)	0.697	0.91 (0.78–1.03)	0.147	0.96 (0.81–1.08)	0.581	0.83 (0.72–0.92)	**0.003**
Nephrotic range proteinuria at baseline	0.43 (0.02–3)	0.464	0.50 (0.02–4.24)	0.549	0.12 (0–1.18)	0.096	1.34 (0.30–9.23)	0.714
eGFR at baseline, ml/min per 1.73 m^2	1.02 (0.99–1.05)	0.085	0.99 (0.95–1.01)	0.510	0.97 (0.92–1.01)	0.375	0.98 (0.96–1.0)	0.056
Time on CoQ$_{10}$ treatment, yr	0.99 (0.79–1.36)	0.963	3.22 (1.13–29)	0.139	1.41 (0.81–2.75)	0.234	1.03 (0.88–1.17)	0.607
CoQ$_{10}$ dosage, mg/kg per d	1.03 (0.96–1.11)	0.372	1.01 (0.93–1.11)	0.664	1.01 (0.93–1.10)	0.744	1.08 (1.01–1.16)	**0.021**
Late CoQ$_{10}$ initiation (≥1 y from disease onset)	1.61 (0.32–12.0)	0.586	3.50 (0.45–73)	0.288	4.33 (0.77–28.66)	0.103	0.56 (0.14–1.90)	0.371
Concomitant RAASi treatment	0.76 (0.16–3.26)	0.714	1.37 (0.25–7.53)	0.706	1.33 (0.27–6.90)	0.721	0.54 (0.15–1.81)	0.317
FSGS	1.06 (0.12–6.62)	0.946	1.66 (0.06–24.9)	0.713	1.25 (0.09–31.16)	0.868	4.43 (0.77–83.4)	0.165
Dysmorphic mitochondria	1.73 (0.29–14)	0.560	0.33 (0.02–3.77)	0.361	1.16 (0.11–10.46)	0.889	1.4 (0.27–6.42)	0.657
Proteinuria reduction ≥50% in first 6 mo	N/A	N/A	N/A	N/A	N/A	N/A	0.28 (0.01–1.66)	0.242

CI, confidence interval; CoQ$_{10}$, coenzyme Q10; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; FSGS, focal segmental glomerular sclerosis; HR, hazard ratio; N/A, not applicable; OR, odds ratio; RAASi, renin-angiotensin-aldosterone system inhibitors; UPCR, urine protein-to-creatinine ratio.
[a]A ≥50% reduction in proteinuria from pretreatment baseline (normalization of serum albumin in case of missing proteinuria information).
A total of 68 patients with chronic kidney disease stage 1 to 4 at start of therapy were included in the analyses. Bold data indicate significant P values.

Figure 2 | Five-year end-stage kidney disease–free survival rates of treated (blue) versus matched untreated control patients (gray). (**a**) All patients. (**b**) *COQ2* subcohort. (**c**) *COQ6* subcohort. (**d**) *COQ8B* subcohort.

reduction or progression to ESKD while on CoQ$_{10}$ supplementation.

DISCUSSION

In this study, we undertook a comprehensive effort involving worldwide data collection to obtain real-world information about the short- and long-term efficacy and safety of oral CoQ$_{10}$ supplementation in hereditary CoQ$_{10}$ deficiency, an ultrarare, genetically heterogeneous disorder that can cause glomerular proteinuria and focal-segmental glomerulosclerosis, leading to ESKD.

Although almost half of the 251 identified patients received oral CoQ$_{10}$ supplements for some time, in more than half of these cases treatment was applied only after they had progressed to ESKD, baseline biochemical information was lacking, or treatment was temporarily interrupted. However, in those patients in whom sufficient data were available to assess the impact of therapy on kidney function end points, we documented remarkable effects.

Proteinuria decreased substantially, on average by >80% at first 12 months and remained around 40% of baseline value during up to 5 years of follow-up on treatment. These findings confirm and extend previous observations in individual patients and small case series and suggest a sustained effect of CoQ$_{10}$ supplementation on podocyte survival and function.[8] The proteinuria-lowering effect was observed in patients across *COQ2*, *COQ6*, and *COQ8B*

deficiency cohorts; however, complete remission of proteinuria occurred more frequently in patients with *COQ6* disease. CoQ$_{10}$ responsiveness did not differ between patients with truncating and missense mutations, which is not surprising given the fact that the therapeutic intervention acts downstream of the mutated proteins of the CoQ$_{10}$ synthase complex.

Our findings support the notion that administration of CoQ$_{10}$ can compensate for deficient endogenous synthesis irrespective of the molecular defect affecting the integrity of the CoQ$_{10}$ synthase complex. Hence, our data are compatible with the notion that effective CoQ$_{10}$ supply can restore podocyte energy balance, reversing effacement and improving cell survival.[8]

In addition to proteinuria as a surrogate outcome marker, extended patient follow-up and comparison with a matched untreated patient cohort allowed us to assess the impact of CoQ$_{10}$ supplementation on longer-term kidney survival. We observed a substantially longer preservation of kidney function in children treated with CoQ$_{10}$, with a nearly 2-fold higher 5-year kidney survival rate across the 3 genetic entities. In line with these findings, annualized rates of eGFR loss were considerably lower in the CoQ$_{10}$-supplemented patients. No nephroprotective effect was seen in patients with *COQ8B* deficiency, possibly related to the typically late diagnosis and more advanced CKD at treatment initiation in this subgroup.

Responses of other systems affected in CoQ$_{10}$ deficiency to supplementation were not uniform. Although new-onset and progressive neurologic disease manifestations were reported during CoQ$_{10}$ therapy in some patients, 10% to 20% of treated individuals achieved neurologic improvement. In some patients, seizures and headaches ceased and never recurred while on treatment. Some investigators also reported improvements of the general clinical condition with CoQ$_{10}$ supplementation with better clinical performance, facilitated feeding, and improved weight gain. Although these observations are limited by their retrospective nature, lacking standardization of assessment, and the absence of untreated controls, our findings add some support to potential beneficial systemic effects of CoQ$_{10}$ therapy.

The intestinal absorption of CoQ$_{10}$ resembles that of other lipophilic substances[18]; its bioavailability can be affected by diet, microbiota, and the intestinal absorption capacity for lipids.[19,20] Hence, the restoration of cellular CoQ$_{10}$ content during supplementation is likely to vary widely between individuals, and hyporesponsiveness to therapy may be due to inadequate intestinal CoQ$_{10}$ uptake. Unfortunately, biomarkers indicating the adequacy of CoQ$_{10}$ supplementation are currently not available. Serum CoQ$_{10}$ concentration and the CoQ$_{10}$ content of peripheral leukocytes are not correlated with the disease course; indeed, levels may be normal even with significant disease[21] or be low despite clinical remission.[22] Measurement of CoQ$_{10}$ content in skeletal muscle would require an invasive procedure, and measurement in fibroblast cultures would not reflect the *in vivo* availability of supplemented CoQ$_{10}$. However, dose-optimization studies using proteinuria as a pharmacodynamic readout might allow individualization of CoQ$_{10}$ supplementation.

Efforts to maximize treatment efficacy by dose escalation may be limited by gastrointestinal tolerability. Although the overall safety and tolerability profile of oral CoQ$_{10}$ therapy was excellent, gastrointestinal irritation was the main reported adverse effect. However, at the dose range administered, gastrointestinal effects required treatment discontinuation in <2% of treated patients, suggesting some potential for application of higher doses in at least a fraction of the patients.

RAAS inhibitor comedication was applied in one-third of the patients as a baseline antiproteinuric therapy in SRNS. RAAS inhibitor coadministration was not associated with an increased likelihood of achieving 50% proteinuria reduction during CoQ$_{10}$ treatment nor with improved kidney survival during follow-up. We assume that the profound effect of CoQ$_{10}$ supplementation on podocyte function exceeded any beneficial effect of RAAS inhibition on proteinuria and long-term kidney function.

We acknowledge some important limitations of this study. In view of the ultrarare nature of the disease and the even more limited experience with CoQ$_{10}$ treatment, we chose to collect any retrospective data available from the clinical records. This resulted in a set of nonstandardized, variably complete data that required us to make various assumptions

and approximations, in particular with regard to proteinuria and eGFR measurements. Also, we are lacking information about long-term treatment adherence. Furthermore, although great care was taken to exclude selection bias when matching cases and controls for kidney survival analysis, some bias may have resulted from the historical nature of the controls. The validity of the actuarial survival and Cox regression analyses was also limited by the small patient numbers per disease group and the relatively short follow-up on treatment.

Nonetheless, our findings clearly support the inclusion of CoQ$_{10}$ pathway genes in SRNS screening panels and the administration of oral CoQ$_{10}$ supplements in all patients diagnosed with primary CoQ$_{10}$ deficiency.[23] CoQ$_{10}$ treatment can potentially slow down or prevent kidney disease progression and may also impact beneficially on other mitochondriopathic organ manifestations. The availability of an effective therapy should also prompt early diagnostic assessment in siblings of index cases.

REFERENCES

1. Lipska-Ziętkiewicz BS. Genetic steroid-resistant nephrotic syndrome overview. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. *GeneReviews®* [Internet]. Seattle: University of Washington; 1993–2022. Accessed June 10, 2022. https://www.ncbi.nlm.nih.gov/books/NBK573219
2. Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. *J Am Soc Nephrol*. 2017;28:3055–3065.
3. Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. *J Am Soc Nephrol*. 2015;26:1279–1289.
4. Rao J, Liu X, Mao J, et al. Genetic spectrum of renal disease for 1001 Chinese children based on a multicenter registration system. *Clin Genet*. 2019;96:402–410.
5. Trautmann A, Lipska-Zietkiewicz BS, Schaefer F. Exploring the clinical and genetic spectrum of steroid resistant nephrotic syndrome: the PodoNet Registry. *Front Pediatr*. 2018;6:200.
6. Schijvens AM, van de Kar NC, Bootsma-Robroeks CM, et al. Mitochondrial disease and the kidney with a special focus on CoQ10 deficiency. *Kidney Int Rep*. 2020;5:2146–2159.
7. Warejko JK, Tan W, Daga A, et al. Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol*. 2018;13:53–62.
8. Kleiner G, Barca E, Ziosi M, et al. CoQ10 supplementation rescues nephrotic syndrome through normalization of H2S oxidation pathway. *Biochim Biophys Acta Mol Basis Dis*. 2018;1864:3708–3722.
9. Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies. *Nat Rev Drug Discov*. 2021;20:770–788.
10. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N Engl J Med*. 2008;358:2849–2850.
11. Atmaca M, Gulhan B, Atayar E, et al. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. *Turk J Pediatr*. 2019;61:657–663.
12. Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. *Pediatr Nephrol*. 2017;32:1369–1375.
13. Korkmaz E, Lipska-Zietkiewicz BS, Boyer O, et al. ADCK4-associated glomerulopathy causes adolescence-onset FSGS. *J Am Soc Nephrol*. 2016;27:63–68.
14. Eroglu FK, Ozaltin F, Gonc N, et al. Response to early coenzyme Q10 supplementation is not sustained in CoQ10 deficiency caused by CoQ2 mutation. *Pediatr Neurol*. 2018;88:71–74.
15. Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest*. 2011;121:2013–2024.
16. Abdelhakim AH, Dharmadhikari AV, Ragi SD, et al. Compound heterozygous inheritance of two novel COQ2 variants results in familial coenzyme Q deficiency. *Orphanet J Rare Dis*. 2020; 15:320.
17. Drovandi S, Lipska-Ziętkiewicz BS, Ozatlin F, et al. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy. *Kidney Int*. 2022;102: 592–603.
18. Miles MV. The uptake and distribution of coenzyme Q10. *Mitochondrion*. 2007;7(suppl):S72–S77.
19. Martucci A, Reurean-Pintilei D, Manole A. Bioavailability and sustained plasma concentrations of CoQ10 in healthy volunteers by a novel oral timed-release preparation. *Nutrients*. 2019;11:527.
20. Arenas-Jal M, Sune-Negre JM, Garcia-Montoya E. Coenzyme Q10 supplementation: efficacy, safety, and formulation challenges. *Compr Rev Food Sci Food Saf*. 2020;19:574–594.
21. Starr MC, Chang IJ, Finn LS, et al. COQ2 nephropathy: a treatable cause of nephrotic syndrome in children. *Pediatr Nephrol*. 2018;33: 1257–1261.
22. Stanczyk M, Balasz-Chmielewska I, Lipska-Zietkiewicz B, Tkaczyk M. CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report. *Pediatr Nephrol*. 2018;33:2383–2387.
23. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol*. 2020;35:1529–1561.